Liege, Belgium, 10 August 2022 – 18:45 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra“), a company dedicated to Women’s Health, today announces that, following the first drawdown by the Company under the loan facility concluded with funds managed by Highbridge Capital Management, LLC (“Highbridge“) and funds managed by Whitebox Advisors, LLC (“Whitebox“, and together with Highbridge, each a “Lender”), a first portion of the commitment fee due by the Company was settled in new shares, and a first portion of the loans were contributed in kind by the Lenders against the issuance of new shares.

Liege, Belgium, 8 August 2022 – 8:30 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, announces today that it has entered into a senior secured convertible facilities agreement with funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”) and funds managed by Whitebox Advisors LLC (collectively, “Whitebox”, and together with Highbridge, each a “Lender”), for a three year term, in an amount of up to EUR 100 million. Part of the proceeds of the loan will be used to repurchase outstanding convertible bonds of the Company held by the Lenders for a principal amount of EUR 34.1 million at a discount.

8 August 2022, 07:30, Adelaide, Australia and Liege, Belgium – Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce that the US Food and Drug Administration (FDA) has granted approval of the Abbreviated New Drug Application (ANDA) for HALOETTE® (etonogestrel and ethinyl estradiol) vaginal hormonal contraceptive ring. Mayne Pharma anticipates the commercial launch of HALOETTE® ring by early calendar year 2023.

2 August 2022, 07:30 CEST, Adelaide, Australia and Liege, Belgium – Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce NEXTSTELLIS® (drospirenone and estetrol tablets) has been nominated for the 2022 Prix Galien USA Award for Best Pharmaceutical Agent. After France and Belgium, the contraceptive developed by Mithra is selected for the third time by the Galien Prize, the most prestigious award of the pharmaceutical research and innovation.

 

Liege, Belgium, 01 August 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that its U.S. commercial partner, Mayne Pharma Group Limited (ASX: MYX), has entered into a new strategic collaboration with GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer (DTC) program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States.

26 July 2022, 07:30 CEST Adelaide, Australia and Liege, Belgium – Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce NEXTSTELLIS® (14.2 mg of estetrol and 3 mg drospirenone tablets), the first-of-its-kind oral contraceptive with a novel estrogen, is now available in Australia.

Liege, Belgium, 6 July 2022 – 17:45 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces a change in its Board of Directors’ Chairmanship. Following the resignation with immediate effect of Mr. Ajit Shetty for personal reasons nonrelated to the Company, the Board of Directors approved, on the proposal of the outgoing Chairman and the recommendation of the Nomination and Remuneration Committee, the appointment of Mr. Christian Moretti as Chairman, as well as that of Mr. Erik Van Den Eynden as Vice-Chairman. These functions will be exercised until the next Company’s Shareholders Meeting in May 2023 called to deliberate on the renewal of the Board at the end of the members’ terms of office.

Liege, Belgium, 30 June 2022 – 17:45 CEST – In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the below information, following the issuance of 625,000 new shares today for a total amount of EUR 4,133,933 following the Put Option Notice issued on 13 May, 2022 in the framework of LDA capital commitment agreement entered into April 2020 and extended in April 2022.

Liege, Belgium, 24 June 2022 –18:00 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, today announces that it completed the private placement of 3,871,491 new shares for an aggregate amount of EUR 23.5 million that it had announced on 21 June 2022 (the “Private Placement”).

As a result of the completion of the Private Placement, the share capital of the Company was increased from EUR 33,739,072.34 to EUR 36,573,390.90 and the number of issued and outstanding shares of the Company was increased from 46,085,634 to 49,957,125 ordinary shares, through the issuance of a total of 3,871,491 new shares at an issue price of EUR 6.07 per new share.

Liege, Belgium, 21 June 2022 –07.30 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, today announces that it received subscription commitments from professional, qualified, institutional and other private investors for an aggregate amount of EUR 23.5 million, to subscribe for an aggregate of 3,871,471 new ordinary shares of the Company (being approximately 8.4% of the Company’s outstanding shares) at an issue price of EUR 6.07 per share, representing a 5% discount to the closing share price on Friday 17 June 2022 (the “Private Placement”).